ADC Therapeutics SA (ADCT) Stock Forecast, Price Target & Predictions
ADCT Stock Forecast
ADC Therapeutics SA stock forecast is as follows: an average price target of $9.33 (represents a 200.97% upside from ADCT’s last price of $3.10) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
ADCT Price Target
The average price target for ADC Therapeutics SA (ADCT) is $9.33 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $13.00 to $7.00. This represents a potential 200.97% upside from ADCT's last price of $3.10.
ADCT Analyst Ratings
According to 7 Wall Street analysts, ADC Therapeutics SA's rating consensus is 'Buy'. The analyst rating breakdown for ADCT stock is 0 'Strong Buy' (0.00%), 4 'Buy' (57.14%), 3 'Hold' (42.86%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
ADC Therapeutics SA Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 07, 2024 | Robert Burns | H.C. Wainwright | $8.00 | $4.45 | 79.78% | 158.06% |
| Mar 13, 2024 | Kelly Shi | Jefferies | $13.00 | $3.90 | 233.33% | 319.35% |
| Nov 14, 2022 | - | Morgan Stanley | $7.00 | $4.10 | 70.73% | 125.81% |
| Sep 09, 2022 | Matthew Harrison | Morgan Stanley | $11.00 | $6.52 | 68.71% | 254.84% |
| Aug 22, 2022 | - | H.C. Wainwright | $20.00 | $8.42 | 137.53% | 545.16% |
The latest ADC Therapeutics SA stock forecast, released on May 07, 2024 by Robert Burns from H.C. Wainwright, set a price target of $8.00, which represents a 79.78% increase from the stock price at the time of the forecast ($4.45), and a 158.06% increase from ADCT last price ($3.10).
ADC Therapeutics SA Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 2 |
| Avg Price Target | - | - | $10.50 |
| Last Closing Price | $3.10 | $3.10 | $3.10 |
| Upside/Downside | -100.00% | -100.00% | 238.71% |
In the current month, the average price target of ADC Therapeutics SA stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to ADC Therapeutics SA's last price of $3.10. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| May 30, 2024 | Cantor Fitzgerald | - | Overweight | Initialise |
| May 07, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Feb 20, 2024 | Needham | Buy | Buy | Hold |
| Aug 10, 2023 | Deutsche Bank | - | Hold | Downgrade |
| Aug 10, 2023 | Citigroup | - | Neutral | Downgrade |
| Nov 14, 2022 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| Sep 19, 2022 | H.C. Wainwright | Buy | Buy | Hold |
| May 10, 2022 | RBC Capital | Outperform | Outperform | Hold |
ADC Therapeutics SA's last stock rating was published by Cantor Fitzgerald on May 30, 2024. The company Initialise its ADCT rating from "null" to "Overweight".
ADC Therapeutics SA Financial Forecast
ADC Therapeutics SA Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $16.79M | $14.49M | - | $18.99M | $69.80M | $76.32M | - | $46.50M | $17.01M | $13.15M | $3.76M | - | - | - | - |
| Avg Forecast | $23.06M | $21.84M | $20.81M | $19.98M | $19.10M | $18.37M | $18.89M | $18.04M | $15.31M | $15.15M | $20.25M | $20.12M | $39.38M | $60.70M | $31.22M | $37.12M | $16.47M | $7.39M | $2.23M | $94.33K | $858.00K | $42.67K | $599.00K |
| High Forecast | $24.19M | $22.91M | $21.83M | $20.96M | $20.04M | $18.91M | $19.81M | $18.93M | $15.60M | $15.90M | $21.24M | $21.11M | $41.31M | $63.67M | $31.22M | $38.88M | $17.26M | $7.74M | $2.33M | $98.83K | $898.86K | $44.70K | $627.52K |
| Low Forecast | $22.10M | $20.92M | $19.93M | $19.14M | $18.30M | $17.86M | $18.09M | $17.29M | $14.93M | $14.52M | $19.40M | $19.28M | $37.73M | $58.15M | $31.22M | $34.10M | $15.14M | $6.79M | $2.04M | $86.67K | $788.33K | $39.20K | $550.36K |
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Surprise % | - | - | - | - | - | - | - | - | 1.10% | 0.96% | - | 0.94% | 1.77% | 1.26% | - | 1.25% | 1.03% | 1.78% | 1.69% | - | - | - | - |
ADC Therapeutics SA's average Quarter revenue forecast for Mar 24 based on 2 analysts is $18.04M, with a low forecast of $17.29M, and a high forecast of $18.93M. ADCT's average Quarter revenue forecast represents a 7.47% increase compared to the company's last Quarter revenue of $16.79M (Dec 23).
ADC Therapeutics SA EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| EBITDA | - | - | - | - | - | - | - | - | $-41.97M | $-34.20M | - | $-48.52M | $-10.39M | $7.44M | - | $-23.96M | $-80.72M | $-66.47M | $-68.90M | $-49.24M | $-52.57M | $-17.76M | $-125.02M |
| Avg Forecast | $-11.40M | $-10.79M | $-10.28M | $-9.87M | $-9.44M | $-9.08M | $-9.33M | $-8.92M | $-7.57M | $-7.49M | $-10.01M | $-9.94M | $-19.46M | $-29.99M | $-15.43M | $-18.34M | $-8.14M | $-79.66M | $-60.09M | $-46.62K | $-424.00K | $-54.50M | $-39.04M |
| High Forecast | $-10.92M | $-10.34M | $-9.85M | $-9.46M | $-9.04M | $-8.83M | $-8.94M | $-8.54M | $-7.38M | $-7.17M | $-9.59M | $-9.53M | $-18.65M | $-28.74M | $-15.43M | $-16.85M | $-7.48M | $-63.73M | $-48.07M | $-42.83K | $-389.57K | $-43.60M | $-31.23M |
| Low Forecast | $-11.96M | $-11.32M | $-10.79M | $-10.36M | $-9.90M | $-9.34M | $-9.79M | $-9.35M | $-7.71M | $-7.86M | $-10.50M | $-10.43M | $-20.42M | $-31.46M | $-15.43M | $-19.21M | $-8.53M | $-95.60M | $-72.10M | $-48.84K | $-444.19K | $-65.40M | $-46.85M |
| Surprise % | - | - | - | - | - | - | - | - | 5.55% | 4.57% | - | 4.88% | 0.53% | -0.25% | - | 1.31% | 9.92% | 0.83% | 1.15% | 1056.20% | 123.99% | 0.33% | 3.20% |
1 analysts predict ADCT's average Quarter EBITDA for Dec 22 to be $-19.46M, with a high of $-18.65M and a low of $-20.42M. This is -361.63% lower than ADC Therapeutics SA's previous annual EBITDA (Sep 22) of $7.44M.
ADC Therapeutics SA Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Net Income | - | - | - | - | - | - | - | - | $-85.03M | $-47.81M | - | $-59.43M | $-24.16M | $-50.61M | - | $-16.66M | $-34.38M | $-71.55M | $-72.57M | $-51.53M | $-55.93M | $-20.33M | $-126.56M |
| Avg Forecast | $-38.91M | $-37.96M | $-37.64M | $-36.36M | $-36.91M | $-36.23M | $-43.75M | $-53.18M | $-48.04M | $-60.67M | $-66.95M | $-1.91M | $-46.25M | $-33.77M | $-65.90M | $-55.41M | $-69.60M | $-85.74M | $-63.07M | $-74.47M | $-40.65M | $-21.33M | $-110.98M |
| High Forecast | $-36.79M | $-35.89M | $-35.59M | $-34.38M | $-34.90M | $-32.09M | $-41.37M | $-50.28M | $-20.42M | $-57.36M | $-63.30M | $-1.81M | $-43.73M | $-31.93M | $-65.90M | $-49.56M | $-62.25M | $-68.59M | $-50.45M | $-66.61M | $-36.36M | $-17.07M | $-88.78M |
| Low Forecast | $-41.39M | $-40.38M | $-40.04M | $-38.68M | $-39.26M | $-37.26M | $-46.54M | $-56.57M | $-64.86M | $-64.53M | $-71.21M | $-2.04M | $-49.20M | $-35.92M | $-65.90M | $-58.84M | $-73.90M | $-102.88M | $-75.68M | $-79.08M | $-43.17M | $-25.60M | $-133.18M |
| Surprise % | - | - | - | - | - | - | - | - | 1.77% | 0.79% | - | 31.05% | 0.52% | 1.50% | - | 0.30% | 0.49% | 0.83% | 1.15% | 0.69% | 1.38% | 0.95% | 1.14% |
ADC Therapeutics SA's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ADCT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
ADC Therapeutics SA SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| SG&A | - | - | - | - | - | - | - | - | $25.22M | $23.09M | - | $30.49M | $31.31M | $36.46M | - | $37.38M | $36.53M | $33.63M | $34.59M | $31.49M | $29.45M | $20.27M | $19.00M |
| Avg Forecast | $60.50M | $57.28M | $54.58M | $52.41M | $50.10M | $48.18M | $49.54M | $47.33M | $40.17M | $39.75M | $53.11M | $52.78M | $103.30M | $159.20M | $81.90M | $97.35M | $43.21M | $19.37M | $5.84M | $247.43K | $2.25M | $111.91K | $1.57M |
| High Forecast | $63.46M | $60.09M | $57.25M | $54.98M | $52.55M | $49.60M | $51.96M | $49.65M | $40.92M | $41.70M | $55.72M | $55.37M | $108.36M | $167.00M | $81.90M | $101.99M | $45.27M | $20.29M | $6.11M | $259.21K | $2.36M | $117.24K | $1.65M |
| Low Forecast | $57.96M | $54.88M | $52.29M | $50.21M | $48.00M | $46.85M | $47.46M | $45.35M | $39.15M | $38.08M | $50.89M | $50.57M | $98.97M | $152.53M | $81.90M | $89.45M | $39.70M | $17.80M | $5.36M | $227.33K | $2.07M | $102.82K | $1.44M |
| Surprise % | - | - | - | - | - | - | - | - | 0.63% | 0.58% | - | 0.58% | 0.30% | 0.23% | - | 0.38% | 0.85% | 1.74% | 5.93% | 127.28% | 13.09% | 181.15% | 12.09% |
ADC Therapeutics SA's average Quarter SG&A projection for Mar 24 is $47.33M, based on 2 Wall Street analysts, with a range of $45.35M to $49.65M. The forecast indicates a 87.65% rise compared to ADCT last annual SG&A of $25.22M (Dec 23).
ADC Therapeutics SA EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| EPS | - | - | - | - | - | - | - | - | $-1.03 | $-0.58 | - | $-0.74 | $-0.30 | $-0.65 | - | $-0.22 | $-0.45 | $-0.93 | $-0.95 | $-0.67 | $-0.73 | $-0.29 | $-2.01 |
| Avg Forecast | $-0.41 | $-0.40 | $-0.39 | $-0.38 | $-0.39 | $-0.38 | $-0.46 | $-0.56 | $-0.50 | $-0.63 | $-0.70 | $-0.02 | $-0.48 | $-0.35 | $-0.80 | $-0.67 | $-0.85 | $-0.92 | $-0.86 | $-0.91 | $-0.49 | $-0.77 | $-0.65 |
| High Forecast | $-0.38 | $-0.38 | $-0.37 | $-0.36 | $-0.36 | $-0.34 | $-0.43 | $-0.53 | $-0.21 | $-0.60 | $-0.66 | $-0.02 | $-0.46 | $-0.33 | $-0.80 | $-0.60 | $-0.76 | $-0.82 | $-0.77 | $-0.81 | $-0.44 | $-0.69 | $-0.58 |
| Low Forecast | $-0.43 | $-0.42 | $-0.42 | $-0.40 | $-0.41 | $-0.39 | $-0.49 | $-0.59 | $-0.68 | $-0.67 | $-0.74 | $-0.02 | $-0.51 | $-0.38 | $-0.80 | $-0.72 | $-0.90 | $-0.97 | $-0.91 | $-0.96 | $-0.52 | $-0.82 | $-0.69 |
| Surprise % | - | - | - | - | - | - | - | - | 2.05% | 0.91% | - | 37.00% | 0.62% | 1.84% | - | 0.33% | 0.53% | 1.01% | 1.10% | 0.74% | 1.48% | 0.38% | 3.09% |
According to undefined Wall Street analysts, ADC Therapeutics SA's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ADCT previous annual EPS of $NaN (undefined).
ADC Therapeutics SA Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ALVR | AlloVir | $0.75 | $34.00 | 4433.33% | Buy |
| IPSC | Century Therapeutics | $1.60 | $20.00 | 1150.00% | Buy |
| ALXO | ALX Oncology | $2.22 | $24.50 | 1003.60% | Buy |
| PASG | Passage Bio | $0.81 | $6.00 | 640.74% | Buy |
| ADCT | ADC Therapeutics SA | $3.10 | $9.33 | 200.97% | Buy |
| ARVN | Arvinas | $25.05 | $75.36 | 200.84% | Buy |
| FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
| BDTX | Black Diamond Therapeutics | $6.19 | $14.75 | 138.29% | Buy |
| STOK | Stoke Therapeutics | $14.47 | $33.75 | 133.24% | Buy |
| RARE | Ultragenyx Pharmaceutical | $58.74 | $108.14 | 84.10% | Buy |
| DSGN | Design Therapeutics | $5.54 | $9.67 | 74.55% | Buy |
| AKRO | Akero Therapeutics | $27.34 | $43.50 | 59.11% | Buy |
| KURA | Kura Oncology | $20.88 | $28.67 | 37.31% | Buy |
| CRNX | Crinetics Pharmaceuticals | $53.80 | $70.14 | 30.37% | Buy |
| RNA | Avidity Biosciences | $41.71 | $50.00 | 19.88% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $43.70 | $51.20 | 17.16% | Buy |
| PTGX | Protagonist Therapeutics | $47.02 | $50.00 | 6.34% | Buy |
| AADI | Aadi Bioscience | $1.80 | $1.63 | -9.44% | Hold |
ADCT Forecast FAQ
Is ADC Therapeutics SA a good buy?
Yes, according to 7 Wall Street analysts, ADC Therapeutics SA (ADCT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 57.14% of ADCT's total ratings.
What is ADCT's price target?
ADC Therapeutics SA (ADCT) average price target is $9.33 with a range of $7 to $13, implying a 200.97% from its last price of $3.1. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will ADC Therapeutics SA stock go up soon?
According to Wall Street analysts' prediction for ADCT stock, the company can go up by 200.97% (from the last price of $3.1 to the average price target of $9.33), up by 319.35% based on the highest stock price target, and up by 125.81% based on the lowest stock price target.
Can ADC Therapeutics SA stock reach $5?
ADCT's average twelve months analyst stock price target of $9.33 supports the claim that ADC Therapeutics SA can reach $5 in the near future.
What are ADC Therapeutics SA's analysts' financial forecasts?
ADC Therapeutics SA's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $74.4M (high $77.69M, low $71.54M), average EBITDA is $-36.767M (high $-35.354M, low $-38.39M), average net income is $-170M (high $-159M, low $-180M), average SG&A $195.15M (high $203.76M, low $187.65M), and average EPS is $-1.777 (high $-1.658, low $-1.877). ADCT's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $85.69M (high $89.89M, low $82.1M), average EBITDA is $-42.346M (high $-40.571M, low $-44.421M), average net income is $-151M (high $-143M, low $-160M), average SG&A $224.76M (high $235.78M, low $215.34M), and average EPS is $-1.577 (high $-1.491, low $-1.677).
Did the ADCT's actual financial results beat the analysts' financial forecasts?
Based on ADC Therapeutics SA's last annual report (Dec 2023), the company's revenue was $69.06M, which missed the average analysts forecast of $70.84M by -2.51%. Apple's EBITDA was $-166M, beating the average prediction of $-35.007M by 374.14%. The company's net income was $-240M, beating the average estimation of $-178M by 35.19%. Apple's SG&A was $-9.04M, missing the average forecast of $185.81M by -104.87%. Lastly, the company's EPS was $-2.94, beating the average prediction of $-1.856 by 58.43%. In terms of the last quarterly report (Dec 2023), ADC Therapeutics SA's revenue was $16.79M, beating the average analysts' forecast of $15.31M by 9.64%. The company's EBITDA was $-41.966M, beating the average prediction of $-7.567M by 454.57%. ADC Therapeutics SA's net income was $-85.031M, beating the average estimation of $-48.043M by 76.99%. The company's SG&A was $25.22M, missing the average forecast of $40.17M by -37.21%. Lastly, the company's EPS was $-1.03, beating the average prediction of $-0.502 by 105.15%